Michael Alexander Smith Sells 407 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) VP Michael Alexander Smith sold 407 shares of the company’s stock in a transaction that occurred on Tuesday, January 11th. The shares were sold at an average price of $25.11, for a total value of $10,219.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Alexander Smith also recently made the following trade(s):

  • On Wednesday, January 5th, Michael Alexander Smith sold 749 shares of Insmed stock. The stock was sold at an average price of $27.61, for a total value of $20,679.89.

Shares of NASDAQ:INSM opened at $23.73 on Friday. Insmed Incorporated has a 52 week low of $22.00 and a 52 week high of $45.44. The company has a debt-to-equity ratio of 1.13, a quick ratio of 7.92 and a current ratio of 8.52. The firm’s 50 day moving average is $28.05 and its two-hundred day moving average is $27.35.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 28th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.13). Insmed had a negative return on equity of 108.34% and a negative net margin of 243.96%. The business had revenue of $46.80 million for the quarter, compared to the consensus estimate of $49.23 million. During the same quarter in the previous year, the business posted ($0.63) earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts predict that Insmed Incorporated will post -3.77 earnings per share for the current fiscal year.

A number of research firms have recently commented on INSM. Cantor Fitzgerald began coverage on Insmed in a report on Friday, October 8th. They set an “overweight” rating and a $60.00 price objective for the company. Zacks Investment Research cut shares of Insmed from a “hold” rating to a “sell” rating in a research report on Thursday, December 30th. JPMorgan Chase & Co. started coverage on shares of Insmed in a research report on Monday, December 6th. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $52.00 price objective on shares of Insmed in a research report on Friday, October 8th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $50.67.

Several institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Insmed by 27.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 14,372,685 shares of the biopharmaceutical company’s stock worth $409,047,000 after acquiring an additional 3,070,140 shares during the period. William Blair Investment Management LLC boosted its position in Insmed by 33.5% in the second quarter. William Blair Investment Management LLC now owns 5,026,184 shares of the biopharmaceutical company’s stock valued at $143,045,000 after buying an additional 1,261,948 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Insmed by 9.9% in the second quarter. Vanguard Group Inc. now owns 10,646,706 shares of the biopharmaceutical company’s stock worth $303,004,000 after acquiring an additional 961,181 shares during the last quarter. Polar Capital Holdings Plc raised its stake in shares of Insmed by 92.0% in the third quarter. Polar Capital Holdings Plc now owns 1,798,209 shares of the biopharmaceutical company’s stock worth $49,523,000 after acquiring an additional 861,771 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Insmed by 24.9% in the third quarter. Point72 Asset Management L.P. now owns 3,591,988 shares of the biopharmaceutical company’s stock worth $98,923,000 after acquiring an additional 716,392 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Story: What causes a recession?

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.